In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
The first clinical evidence related to an hydrogel based on Olea europaea leaf extract (EHO‐85) indicated for the healing of wounds of full and partial thickness has been published in the Journal of Clinical Medicine.
We are happy to announce the publication in Pharmaceutics of the first paper related to our hydrogel based on Olea europaea leaf extract (OELE) indicated for the healing of wounds of full and partial thickness.
The publication is based on a study that has been designed and carried out by several authors who come from different areas of basic research and therapeutic management of skin lesions of any depth.
• Acquisition allows Noventure to maintain focus on medical devices and grow therapeutic areas in which it operates
• Medical devices contain Olea Europaea leaf extract, showing healing properties for ulcers and skin wounds
• Innovative products are CE marked and available for licensing worldwide
Barcelona, Spain, April 19, 2021 – Noventure, specialized in licensing innovative substance-based medical devices and specialist food supplements, today announces it has acquired the Ulkox® and Oleoabrax® products, based on an Olea Europaea leaf extract wound-healing technology.
